Altea Therapeutics Appoints Dr. William R. Good to its Board of Directors.

An Experienced Scientific Leader in Transdermal Drug Delivery Responsible for the Successful Commercial Development of Numerous Pharmaceutical Products

ATLANTA -- Altea Therapeutics today announces the appointment of Dr. William R. Good to its Board of Directors.

"We are pleased to welcome such an experienced and successful scientist and thought leader in drug delivery to our Board," said Dr. Eric Tomlinson, President and CEO of Altea Therapeutics. "I anticipate that Bill Good's outstanding contributions to the commercial development of a number of successful drug delivery products, including transdermals, will aid greatly the continued development and expansion of our product portfolio."

"Altea Therapeutics is poised to make significant contributions to pharmaceutical products with its development of the PassPort[TM] Transdermal System for the delivery of proteins, carbohydrates and highly water-soluble low-molecular-weight drugs," commented Dr. Good. "I look forward to assisting the company in its drive towards bringing superior products to the market place with its pharmaceutical partners."

William R. Good is presently a private consultant in the area of pharmaceutical research and development, having recently retired from Watson Pharmaceuticals (previously, TheraTech, Inc.). He also remains as Adjunct Professor of Pharmaceutics at the University of Utah. Dr. Good spent 13 years as Vice President, Research and Development at TheraTech/Watson in Salt Lake City, where he lead the successful development of several transdermal products, including transdermal hormone replacement products and a transdermal product for the treatment of urge incontinence, Oxytrol[R] (oxybutynin TTS). Prior to his tenure at TheraTech/Watson, Dr. Good spent 23 years with Ciba-Geigy Corp. (now Novartis), where he founded the Advanced Drug Delivery department and held a number of management positions in the Pharmaceuticals Division, the last of which was Executive Director of Pharmaceutical Research in the U.S. During his time with Ciba-Geigy, Dr. Good led the overall development of several controlled release products, including Estraderm[R] (estradiol TTS), Habitrol[R] (nicotine TTS), and Acutrim[R] (phenylpropanolamine OROS), as well as a number of other products in the cardiovascular area. He has numerous publications and patents in the pharmaceutics and pharmacology disciplines. Dr. Good received his BS and MS degrees in Chemistry and Chemical Physics from the University of Akron, Akron, Ohio and his PhD in Polymer Chemistry from the Institut fur Makromolekulare Chemie, Hermann-Staudinger-Haus, Albert-Ludwigs Universitat, Freiburg, Germany.

About Altea Therapeutics

Altea Therapeutics is an emerging specialty pharmaceutical company developing and commercializing products based on a new transdermal patch technology that can deliver sustained therapeutic levels of highly water-soluble drugs, carbohydrates, nucleic acids, peptides and proteins through the skin in a convenient, painless, and cost-effective manner.

Altea Therapeutics has demonstrated in several clinical studies that its patented PassPort[TM] transdermal system achieves what existing patches are unable to do, namely the continuous delivery through the skin of compounds that are typically administered by needle injections.

The Company is conducting several clinical trials in the U.S. for its products, including for an insulin transdermal patch that provides continuous delivery of basal levels of insulin for people with diabetes, a fentanyl citrate transdermal patch that provides for rapid and safe management of moderate to severe pain, and an apomorphine hydrochloride transdermal patch for the convenient management of advanced Parkinson's disease. Furthermore, the Company is in pre-clinical development with a number of product candidates, including a low-molecular-weight heparin patch for thromboses, a parathyroid hormone analog transdermal patch for osteoporosis, and an atypical antipsychotic transdermal patch for the management of psychoses.

Additional information about Altea Therapeutics may be found at www.alteatherapeutics.com.

NOTE: Altea Therapeutics, PassPort, Medicines Made Better are either registered trademarks or trademarks of Altea Therapeutics Corporation, in the USA and/or other countries. All other brand names, product names, or trademarks belong to their respective holders.

The statements in this press release regarding the products of Altea Therapeutics in development, product development plans, and projected financial results, are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the ability of Altea Therapeutics to both complete the design, development, and manufacturing process development of its products, manufacture and commercialize its products, obtain product and manufacturing approvals from regulatory agencies, manage its growth and expenses, finance its activities and operations, as well as marketplace acceptance of its products.